Las Vegas, NV -- (SBWIRE) -- 09/27/2013 -- Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental analysis, on NYSE, NASDAQ, AMEX, OTCBB and Pink Sheet Stocks. Let’s have a brief look at: Zalicus Inc(NASDAQ:ZLCS), Eagle Bulk Shipping Inc. (NASDAQ:EGLE), Fibrocell Science Inc(NYSEMKT:FCSC), Generex Biotechnology Corporation(OTCMKTS:GNBT)
Zalicus Inc(NASDAQ:ZLCS) ended lower -0.04% and complete the day at $0.765. The total number of shares changed hands during the day was 2.84million. After opening at $0.77, the stock hit as high as $0.81. However, it traded between $0.43and $0.93over the last twelve months. Zalicus Inc., a biopharmaceutical company, engages in the discovery and development of novel treatments for patients suffering from pain.
Has ZLCS Found The Bottom and Ready To Move Up? Find Out Here
Eagle Bulk Shipping Inc. (NASDAQ:EGLE) closed yesterday at $8.11, a +1.12% increase. Around 2.55 million shares were traded, beating an-average trading volume of 1.38 million shares. The company is now valued at around $135.10 million. Eagle Bulk Shipping Inc., through its subsidiaries, engages in the ocean transportation of various bulk cargoes worldwide.
For How Long EGLE’s Gloss will Attract Investors? Find out via this report
Fibrocell Science Inc(NYSEMKT:FCSC) moved -15.83 percent lower at $4.20 and traded between $4.10 and $5.10 after opening the day at $4.21. Its performance over the last five days remained -10.64%, which stands at -10.64% for a month. Going back further than one month, 1-year performance after recent close was +2700%. Fibrocell Science, Inc., an autologous cellular therapeutic company, together with its subsidiaries, focuses on development of various products for aesthetic, medical, and scientific applications.
Why Should Investors Buy FCSC After the Recent Fall? Just Go Here and Find Out
Generex Biotechnology Corporation(OTCMKTS:GNBT)’s shares drop, losing -2.21 percent to close at $0.0310. The stock is up around +24% this year and -54.41% for the last 12 months. Around 2.45 million shares changed hands yesterday, higher from an-average trading volume of 2.08 million shares. Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
Will GNBT Get Buyers Even After The Recent Rally? Find Out Here
About Value Stock Pick
Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental analysis, on NYSE, NASDAQ, AMEX, OTCBB and Pink Sheet Stocks.
PLEASE NOTE WELL: The employees of ValueStockPick.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site, Press releases or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Please Read Our Full Disclaimer at http://www.valuestockpick.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)